Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Roivant Sciences

Roivant Sciences (NASDAQ: ROIV) insider transactions

In the twelve months to 10 November 2026, executives and directors of Roivant Sciences reported 117 open-market sales of 34,343,625 shares ($895.2m) and 0 open-market purchases, by 12 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Roivant Sciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
3 November 2026Venker EricPresident & Immunovant CEOOpen-market sale, 10b5-1 plan−200,000$36.31999,154Form 4
28 October 2026Venker EricPresident & Immunovant CEOOpen-market sale, 10b5-1 plan−200,000$36.591,199,154Form 4
23 October 2026Momtazee James CDirectorGrant or award+383—112,342Form 4
23 October 2026Momtazee James CDirectorShares withheld for tax−77$36.49112,265Form 4
23 October 2026Oren IlanDirectorGrant or award+810—124,490Form 4
23 October 2026Epperly Melissa B,DirectorGrant or award+513—15,467Form 4
23 October 2026Epperly Melissa B,DirectorShares withheld for tax−116$36.4915,351Form 4
20 October 2026Venker EricPresident & Immunovant CEOOpen-market sale, 10b5-1 plan−185,856$35.091,413,298Form 4
20 October 2026Venker EricPresident & Immunovant CEOOpen-market sale, 10b5-1 plan−14,144$35.421,399,154Form 4
16 October 2026Gline MatthewCEOShares withheld for tax−34,638$33.5316,549,136Form 4
16 October 2026Sukhatme MayukhPresident & CIOShares withheld for tax−19,976$33.5318,563,884Form 4
1 October 2026Epperly Melissa B,DirectorOption exercise, 10b5-1 plan+17,750$4.4632,704Form 4
1 October 2026Epperly Melissa B,DirectorOpen-market sale, 10b5-1 plan−16,850$36.0815,854Form 4
1 October 2026Epperly Melissa B,DirectorOpen-market sale, 10b5-1 plan−900$36.5714,954Form 4
30 September 2026Torti FrankPresident and Vant ChairShares withheld for tax+40,309$36.5713,495,893Form 4
30 September 2026Gline MatthewCEOShares withheld for tax−76,171$36.5716,583,774Form 4
30 September 2026Venker EricPresident & Immunovant CEOOption exercise, 10b5-1 plan+200,000$3.851,799,154Form 4
30 September 2026Venker EricPresident & Immunovant CEOOpen-market sale, 10b5-1 plan−200,000$36.621,599,154Form 4
30 September 2026Sukhatme MayukhPresident & CIOShares withheld for tax−46,879$36.5718,583,860Form 4
20 September 2026Humes JenniferChief Accounting OfficerShares withheld for tax−3,880$39.77106,419Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Roivant Sciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.